News|Videos|May 19, 2025

Compounded GLP-1 RA drugs: GLP-1 RA drugs are no longer in shortage, but compounding customized versions of them may continue, part 1

Fact checked by: Todd Shryock

APC CEO Scott Brunner, CAE, discusses compounding drugs, including the GLP-1 RA antidiabetes and antiobesity medications.

The U.S. Food and Drug Administration has ruled GLP-1 RA drugs are no longer in shortage. That ruling affects how compounding pharmacists may mix those drugs. Scott Brunner, CAE, CEO of the Alliance for Pharmacy Compounding, explains the rules that compounding pharmacists operate under, especially for the antidiabetes and antiobesity drugs that have exploded in popularity.

Newsletter

Stay informed and empowered with Medical Economics enewsletter, delivering expert insights, financial strategies, practice management tips and technology trends — tailored for today’s physicians.

Subscribe Now!

Related Content

Latest CME

Burst CME: Targeted Therapy for Optimal Psoriasis Management
Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

View more
Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management
Video

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

Diana Isaacs, PharmD, BCPS, BC-ADM, BCACP, CDCES, FADCES, FCCP; Anders Carlson, MD; Jennifer B. Green, MD

View more